Popular drug class quiets "drug noise," says researcher ...

The effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be ...

Starting a GLP-1 drug was linked with a 14% overall reduced risk of new substance use disorders and a lower risk of harm for ...

Research suggests the drugs have potential for prevention and harm reduction in substance use disorders, writes Ziyad Al-Aly People taking glucagon-like peptide-1 (GLP-1) receptor agonists often ...

They found that after three years of follow-up, the group taking GLP-1 agonists like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide were 14% less likely to develop substance use disorders ...

GLP-1 receptor agonists used to treat type 2 diabetes and obesity could help reduce risk of addiction to substances like cannabis, alcohol, and cocaine. | Cannabis Sciences ...

A large study of US veterans suggests that diabetes and weight-loss medicines may curb cravings and lower severe addiction outcomes, though clinical trials are still needed.

In older adults with type 2 diabetes (T2D), the initiation of GLP-1 receptor agonists vs drugs such as DPP-4 and SGLT2 inhibitors was associated with an 11% increased risk for fragility fractures.

—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...